14 reports

  • ST-103 - Drug Profile
  • ST-103 - Drug Profile

Forty-one subjects reported at least one treatment emergent adverse event (TEAE).

  • Cardiovascular Disease
  • Lipid Modifying Drug
  • Therapy
  • United States
  • Product Initiative
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Cardiovascular Disease
  • Clinical Trial
  • Drug Development
  • Lipid Modifying Drug
  • World
  • 5. All the trials included are unique trials.
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • Therapy
  • World

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Cardiovascular Disease
  • Clinical Trial
  • Hospital
  • Lipid Modifying Drug
  • World
  • HCP-1105 - DRUG PROFILE

Dyslipidemia - Overview Dyslipidemia - Therapeutics Development NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR DYSLIPIDEMIA, H## 2020 PIPELINE OVERVIEW NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR DYSLIPIDEMIA, H## 2020 Pre-Registration ## ## Phase III ## ## Phase II ## ## Phase I ## ## Preclinical ## ## Di

  • Cholesterol
  • Digestive System Disorder
  • Lipid Modifying Drug
  • Pharmaceutical
  • Amarin Corporation plc
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • Pharmaceutical
  • World

PLOS ONE; ##(##): ##-##.

  • Lipid Modifying Drug
  • AstraZeneca PLC
  • Cerenis
  • Merck & Co., Inc.
  • The Medicines Company
  • CLINICAL TRIAL PROFILE SNAPSHOTS

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Cardiovascular Disease
  • Clinical Trial
  • Lipid Modifying Drug
  • World
  • Product Initiative

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Cardiovascular Disease
  • Clinical Trial
  • Hospital
  • Lipid Modifying Drug
  • World

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Cardiovascular Disease
  • Clinical Trial
  • Hospital
  • Lipid Modifying Drug
  • World
  • EVOLOCUMAB - DRUG PROFILE

FH is one of the most common life-threatening genetic diseases, affecting between ## in ## and ## in ## people (##. ##-##. ## per cent).

  • Cardiovascular Disease
  • Lipid Modifying Drug
  • United States
  • Company
  • Product Initiative
  • EVOLOCUMAB - DRUG PROFILE

Phase III - Trial Details EVOLOCUMAB - DRUG PROFILE Product Description Evolocumab (AMG-##, Repatha) is a monoclonal antibody acts as lipid modifying agent.

  • Cholesterol
  • Lipid Modifying Drug
  • United States
  • Product Initiative
  • Amgen Inc.
  • BEZAFIBRATE ER - DRUG PROFILE
  • EVOLOCUMAB - DRUG PROFILE

Bezafibrate is an agonist of peroxisome proliferator-activated receptor alpha (PPARalpha) with antilipidemic activity.

  • Endocrine Disease
  • Lipid Modifying Drug
  • United States
  • Company
  • Product Initiative
  • AND APO B GENE SILENCERS

THE NUMBER OF MOLECULES IN FIGURE ##. ## BELOW IS MORE THAN ## OWING TO THE CO-DEVELOPMENT OF SOME MOLECULES BY MULTIPLE COMPANIES, IN WHICH CASE THE MOLECULE HAS BEEN COUNTED SEPARATELY FOR EACH DEVELOPER. ## FIGURE ##. ## PIPELINE ANALYSIS: DISTRIBUTION BY DRUG DEVELOPER ## ##

  • Lipid Modifying Drug
  • United States
  • Demand
  • Pfizer Inc.
  • Sanofi S.A.